Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 Apr 10; 23(11):2534-43.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.